CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 61 filers reported holding CABALETTA BIO INC in Q1 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,003 | +7.5% | 77,700 | -31.1% | 0.00% | 0.0% |
| Q1 2023 | $933 | -38.3% | 112,800 | -31.0% | 0.00% | -50.0% |
| Q4 2022 | $1,511 | -99.7% | 163,400 | -76.2% | 0.00% | +100.0% |
| Q3 2022 | $447,000 | +25.9% | 687,461 | +105.2% | 0.00% | – |
| Q2 2022 | $355,000 | -12.3% | 335,000 | +68.0% | 0.00% | – |
| Q1 2022 | $405,000 | +216.4% | 199,400 | +1238.3% | 0.00% | – |
| Q2 2021 | $128,000 | -81.3% | 14,900 | -75.8% | 0.00% | -100.0% |
| Q2 2020 | $685,000 | +621.1% | 61,447 | +372.7% | 0.00% | – |
| Q1 2020 | $95,000 | – | 13,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
| COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
| VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
| Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
| Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
| Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
| TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
| Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |